Although human activated protein C (APC) has been used for years in patients with severe sepsis, trials have shown a lack of efficacy for the product and an increased incidence of bleeding. As a result, further study is needed to determine which patients are appropriate candidates for APC therapy.
You are here
P&T® Journal contents for September 2010
Drug Class Review
Sitagliptin (Januvia) and saxagliptin (Onglyza) provide another option for type-2 diabetes. However, clinicians should consider the cost, the potential for hypoglycemia, and the modest efficacy associated with these agents.
Regulatory and Safety Concerns and Proposed Governmental Policy Changes with Respect to Dietary Supplements
Despite the lack of data from trials of dietary supplements, reports of interactions with drugs are increasing. Proposed changes would enhance the FDA’s authority.
Topics include sitagliptin (Januvia and Janumet), a combination tablet (Tribenzor), and an investigational agent (GFT505).
IncobotulinumtoxinA (Xeomin), indicated for cervical dystonia and blepharo- spasm, and ulipristal acetate (ella), an emergency contraceptive, are discussed.